Assembly Biosciences (ASMB) Total Liabilities (2010 - 2026)

Assembly Biosciences' Total Liabilities history runs 17 years deep, the most recent figure standing at $36.9 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 48.67% year-over-year to $36.9 million in Q1 2026; TTM through Mar 2026 was $36.9 million, a 48.67% decrease from a year earlier, with the FY2025 full-year figure at $50.8 million, down 40.75% from the prior year.
• Total Liabilities fell to $36.9 million in Q1 2026 per ASMB's latest filing, from $50.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $95.7 million in Q4 2023 and bottomed at $9.9 million in Q3 2023.
• The 5-year median for Total Liabilities is $50.8 million (2025), against an average of $47.7 million.
• Across the five-year window, Total Liabilities sank 49.65% in 2022 and surged 648.96% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $19.1 million in 2022, then jumped by 400.4% to $95.7 million in 2023, then slipped by 10.36% to $85.8 million in 2024, then plunged by 40.75% to $50.8 million in 2025, then decreased by 27.42% to $36.9 million in 2026.
• Per Business Quant, the three latest ASMB Total Liabilities figures stand at $36.9 million (Q1 2026), $50.8 million (Q4 2025), and $57.3 million (Q3 2025).